Business Context and Reporting Period
This Form 8-K was filed by Scilex Holding Company on January 3, 2025, reporting events occurring on January 2, 2025. The filing details a material definitive agreement regarding the deferral of debt obligations under the Company's Tranche B Senior Secured Convertible Notes.
Key Financial Metrics and Debt Structure
- Debt Instrument: Tranche B Senior Secured Convertible Note issued October 8, 2024.
- Original Obligation: A quarterly amortization payment of $6,250,000 was originally due on January 2, 2025.
- Payment Made: The Company paid an aggregate of $1.11 million in respect of a portion of the First Amortization Payment and related make-whole interest.
- Equity Consideration: SCLX Stock Acquisition JV agreed to deliver 5,000,000 shares of Scilex common stock to the Noteholders as consideration for the deferral.
- Future Liability: A final installment payment of approximately $25 million under a separate Senior Secured Promissory Note (issued September 21, 2023) is currently due March 21, 2025.
Material Changes and Agreements
The Company entered into deferral and consent letters with its Tranche B Noteholders (Oramed, Nomis Bay, BPY Limited, and 3i, LP). Key changes include:
- Deferral of Amortization: The obligation to make the $6.25 million First Amortization Payment has been deferred from January 2, 2025, to October 8, 2026, contingent upon the execution of a Term Sheet.
- Royalty Grant: Under the Term Sheet, Noteholders will collectively receive a 10-year, 4% royalty on worldwide Net Sales of Gloperba and Elyxyb (excluding Elyxyb sales in Canada).
- Ex-US Product Rights: Noteholders have the option to fund up to 50% of the cash purchase price for Ex-US Product Rights in exchange for proportional commercialization revenues.
- Extension of Senior Note: The transactions are subject to Oramed extending the maturity of a separate $25 million Senior Secured Promissory Note from March 21, 2025, to December 31, 2025.
Outlook, Risks, and Contingencies
The filing highlights significant contingencies regarding the Company's liquidity and debt maturity profile:
- Conditional Deferral: The extension of the Tranche B amortization to 2026 is contingent on the Company securing an extension of the Oramed Senior Secured Promissory Note.
- Creditor Discretion: Oramed has no obligation to provide the necessary extension for the $25 million note, and any extension is dependent on definitive documents acceptable to Oramed in its discretion.
- Security Remedies: The deferral limits Noteholders' rights to exercise certain secured creditor remedies against the assets of SCLX Stock Acquisition JV.
Investor Verification Checklist
- Verify the status of the extension agreement for the $25 million Senior Secured Promissory Note due March 21, 2025.
- Confirm the execution of the definitive agreement regarding the 4% royalty on Gloperba and Elyxyb sales.
- Monitor the delivery of the 5,000,000 Scilex shares to the Noteholders.
- Assess the impact of the deferred $6.25 million payment on the Company's cash flow requirements for the remainder of 2025.